Holen Sie sich die Stockscreener-App
196.25
1.19%
2.3707
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$193.88
Offen:
$194.85
24-Stunden-Volumen:
2.23M
Relative Volume:
0.51
Marktkapitalisierung:
$304.58B
Einnahmen:
$58.80B
Nettoeinkommen (Verlust:
$10.24B
KGV:
59.85
EPS:
3.2788
Netto-Cashflow:
$8.98B
1W Leistung:
+5.60%
1M Leistung:
-5.88%
6M Leistung:
+155.72%
1J Leistung:
+166.93%
1-Tages-Spanne:
$193.55
$196.90
1-Wochen-Bereich:
$182.79
$196.90
52-Wochen-Spanne:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
196.40 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
920.78 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.39 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.83 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
120.25 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
What's Going On With AstraZeneca Stock Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC Stock (AZN) Opened Up by 3.38% on Mar 31: Drivers Behind the Movement - TradingKey
Astrazeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia - Investing.com
ASTRAZENECA : Buy rating from Barclays - marketscreener.com
AstraZeneca (AZN) Reports Positive Results from HPP Clinical Tri - GuruFocus
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
Eyes on Asia: Otsuka, Biogen, AstraZeneca - BioXconomy
ASTRAZENECA : Buy rating from Jefferies - marketscreener.com
AstraZeneca says hypophosphatasia replacement enzyme trials positive - London South East
Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca drug for rare bone disease shows positive trial results - Sharecast.com
ASTRAZENECA : Barclays remains its Buy rating - marketscreener.com
Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
AstraZeneca PLC Stock: Positive Tozorakimab COPD Trial Results Drive Shares Higher Amid Strong Pipel - AD HOC NEWS
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca PLC Stock: Positive COPD Trial Results Bolster Growth Outlook for US-Listed Shares - AD HOC NEWS
US Urges Court to Toss AstraZeneca’s Drug Price Negotiation Suit - Bloomberg Law News
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients - Proactive financial news
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings - AOL.com
AstraZeneca PLC Stock (AZN) Opened Up by 5.70% on Mar 30: Key Drivers Unveiled - TradingKey
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies - TradingView
MOR Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN - MarketBeat
Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed - GlobeNewswire Inc.
ASTRAZENECA : Deutsche Bank remains a Sell rating - marketscreener.com
Dakota Wealth Management Purchases 5,595 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca in FTSE 100 Focus as Oncology Developments Shape Market Attention - Kalkine Media
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
Can AstraZeneca Shape FTSE 100 Momentum? - Kalkine Media
USA Financial Formulas Acquires Shares of 10,063 Astrazeneca Plc $AZN - MarketBeat
Chesley Taft & Associates LLC Acquires 25,985 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca Stock Climbs After Experimental COPD Drug Meets Late-Stage Trial Goals - TIKR.com
iShares World ex U.S. Carbon Transition Readiness Aware Active ETF's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
How Astrazeneca Plc (AZN) Affects Rotational Strategy Timing - Stock Traders Daily
Nordea Investment Management AB Grows Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (NYSE:AZN) Gains Sharply Amid Rising Healthcare Market Strength - Kalkine Media
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors - Yahoo Finance
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results - The Chronicle-Journal
AstraZeneca PLC Bonds — Corporate Bond Rates - TradingView
ETFs Investing in AstraZeneca PLC Stocks - TradingView
AstraZeneca advances Friday, outperforms market - MarketWatch
UK's FTSE 100 Ends Week Little Changed; AstraZeneca Shares Gain - marketscreener.com
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial - TipRanks
Astrazeneca (NYSE:AZN) Shares Gap UpHere's What Happened - MarketBeat
AstraZeneca lung drug gets ‘surprise’ win in COPD trials - BioPharma Dive
FTSE 100 movers: AstraZeneca jumps on COPD drug news; Metlen slumps - London South East
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
ASTRAZENECA : Receives a Buy rating from Barclays - marketscreener.com
ASTRAZENECA : Jefferies maintains a Buy rating - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):